Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3987119 | 0.91 | — | — | |
| SCHEMBL1021565 | 0.87 | HTR4 (0.37) | CYP2D6SMN1; SMN2 | |
| SCHEMBL2980596 | 0.87 | HTR4 (0.37) | CYP2D6SMN1; SMN2 | |
| SCHEMBL1022505 | 0.87 | HTR4 (0.37) | CYP2D6SMN1; SMN2 | |
| SCHEMBL1022503 | 0.87 | HTR4 (0.37) | CYP2D6SMN1; SMN2 | |
| SCHEMBL3981204 | 0.86 | PIK3CD (0.35) | ALDH1A1 | |
| SCHEMBL3979933 | 0.85 | CYP2D6 (0.32) | CYP2D6SMN1; SMN2ALDH1A1 | |
| SCHEMBL3989979 | 0.84 | — | — | |
| SCHEMBL3413738 | 0.83 | KDM1A (0.35) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL3045274 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292223-A1 | INDAZOLE-CARBOXAMIDE COMPOUNDS | THERAVANCE, INC. (US) | 2010-11-18 | — | — | US | claimed |
| EP-1831211-B1 | INDAZOLE-CARBOXAMIDE COMPOUNDS | THERAVANCE INC (US) | 2010-06-02 | — | — | EP | claimed |
| US-20060135764-A1 | Indazole-carboxamide compounds | THERAVANCE, INC. | 2006-06-22 | — | — | US | claimed |
| US-20100292223-A1 | INDAZOLE-CARBOXAMIDE COMPOUNDS | THERAVANCE, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-7786136-B2 | Indazole-carboxamide compounds | THERAVANCE, INC. (US) | 2010-08-31 | — | — | US | disclosed |
| EP-1831211-B1 | INDAZOLE-CARBOXAMIDE COMPOUNDS | THERAVANCE INC (US) | 2010-06-02 | — | — | EP | disclosed |
| US-7419989-B2 | Indazole-carboxamide compounds | THERAVANCE, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20080132491-A1 | Indazole-carboxamide compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-06-05 | — | — | US | disclosed |
| US-20060135764-A1 | Indazole-carboxamide compounds | THERAVANCE, INC. | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292223-A1 | INDAZOLE-CARBOXAMIDE COMPOUNDS | HTR4, HTR5A, HTR3B | CYP2D6 594/4885SMN1; SMN2 3386/4885ALDH1A1 1634/4885 |
| US-20080132491-A1 | Indazole-carboxamide compounds | HTR4, HTR5A, HTR3B | CYP2D6 594/4885SMN1; SMN2 3386/4885ALDH1A1 1634/4885 |
| US-20060135764-A1 | Indazole-carboxamide compounds | HTR4, HTR5A, HTR3B | CYP2D6 594/4885SMN1; SMN2 3386/4885ALDH1A1 1634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.